2025 Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and **Venous Leg Ulcers**

v of blood glucose level/HbA1C, diet, nutrition, activity, on, and assessment of off-loading devices or use of
iss index, history of pulmonary embolism or al inactivity), physical exam (edema, skin changes apetence, and venous thrombosis. The use of a firm we dressing is an essential component of SOC for
tment and outcomes of counseling, if applicable.
ting progression of wound closure under current
lifier.
the medical record, whether the current treatment continue to heal with this plan. Documentation should lications anticipated, and plan of care if healing is not
ocation after previous successful treatment.
duct available at the time of treatment (i.e., if multiple Coding Article has specific guidance around the
aniin tii tii di

EPIFIX® AND EPICORD® REMAIN COVERED!

EPIFIX® Q-Code: Q4186 Covered for: DFUs, VLUs EPICORD® Q-Code: Q4187 Covered for: DFUs



Access your MAC's LCD, Billing & Coding Article, and other important resources: mimedx.info/2025-LCDs



